PCI acquires LSNE, adding fill-finishing to the mix


Transaction enhances CDMO’s services when it comes to drug product offerings

PCI Pharma Services (PCI), a biopharma global outsourcing services provider, has signed an agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a contract development and manufacturing organization (CDMO), expanding its biologic packaging specialty manufacturing experience as a result. LSNE provides services to pharma, biotech and medical device companies, also offering aseptic filling-finishing expertise that complies with current good manufacturing practices (GMPs).

With the acquisition of LSNE, PCI will be able to offer integrated large and small molecule solutions to its clinical and commercial clients. This agreement involves manufacturing capabilities surrounding complex formulations, highly potent agents, and now lyophilization for a plethora of injectables, such as nanoparticles, mRNA, monoclonal antibodies, proteins, oligonucleotides and others. There are also various packaging options, ranging from vials and bottles to pre-filled syringes and auto-injectors.

“We are delighted to welcome LSNE to the PCI family,” says Salim Haffar, CEO of PCI. "… This acquisition will expand our manufacturing capability globally, providing our customers with a single source for their drug development and packaging needs.”

Related Videos
© 2024 MJH Life Sciences

All rights reserved.